MaxCyte Inc’s filing revealed that its Director Johnston John Joseph unloaded Company’s shares for reported $13935.0 on Jan 27 ’25. In the deal valued at $4.64 per share,3,000 shares were sold. As a result of this transaction, Johnston John Joseph now holds 141,950 shares worth roughly $ 0.57 million.
Then, Sandoval David I. sold 4,466 shares, generating $20,272 in total proceeds. Upon selling the shares at $4.54, the GENERAL COUNSEL now owns 41,447 shares.
Before that, Johnston John Joseph sold 3,000 shares. MaxCyte Inc shares valued at $12,021 were divested by the Director at a price of $4.01 per share. As a result of the transaction, Johnston John Joseph now holds 141,950 shares, worth roughly $0.57 million.
Craig Hallum initiated its MaxCyte Inc [MXCT] rating to a Buy in a research note published on November 29, 2023; the price target was $7. William Blair began covering MXCT with “an Outperform” recommendation on August 24, 2021. Wedbush started covering the stock on August 24, 2021. It rated MXCT as “an Outperform”.
Price Performance Review of MXCT
On Tuesday, MaxCyte Inc [NASDAQ:MXCT] saw its stock fall -3.60% to $4.02. Over the last five days, the stock has lost -7.80%. MaxCyte Inc shares have fallen nearly -3.37% since the year began. Nevertheless, the stocks have fallen -13.92% over the past one year. While a 52-week high of $5.26 was reached on 01/21/25, a 52-week low of $3.16 was recorded on 02/18/25. SMA at 50 days reached $4.36, while 200 days put it at $4.18.
Levels Of Support And Resistance For MXCT Stock
The 24-hour chart illustrates a support level at 3.91, which if violated will result in even more drops to 3.81. On the upside, there is a resistance level at 4.17. A further resistance level may holdings at 4.32. The Relative Strength Index (RSI) on the 14-day chart is 39.11, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.27, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 93.12%. Stochastics %K at 11.02% indicates the stock is a buying.
The most recent change occurred on August 24, 2021 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $18 price target.
